Merck’s RSV antibody treatment for infants is approved by FDA

The FDA has approved Merck's Enflonsia (clesrovimab), a monoclonal antibody for RSV prevention in infants under 12 months, priced at $556 per dose, matching Sanofi/AstraZeneca's Beyfortus. While Enflonsia offers a single-dose advantage regardless of weight, it is currently only approved for the first RSV season, unlike Beyfortus, which is also approved for high-risk babies in their second season; Merck is studying potential expansion to this group. The approval introduces a third option to combat RSV, potentially impacting the market and healthcare costs, though uncertainty exists regarding upcoming recommendations from a newly appointed Advisory Committee on Immunization Practices.

Analysis

The U.S. Food and Drug Administration has approved Merck's (MRK) Enflonsia (clesrovimab), a new monoclonal antibody for preventing respiratory syncytial virus (RSV) in infants under 12 months. Enflonsia is priced at $556 per dose, matching its primary competitor, Beyfortus, jointly developed by Sanofi (SNY) and AstraZeneca (AZN). A key differentiating feature for Enflonsia is its single-dose formulation for all infants regardless of weight, which Merck anticipates will simplify administration logistics for pediatricians compared to Beyfortus, which requires weight-based dosing. Currently, Enflonsia is approved only for an infant's first RSV season, whereas Beyfortus also has approval for high-risk infants in their second season; Merck is conducting studies to potentially expand Enflonsia's label to this cohort. This approval introduces a third monoclonal antibody to the RSV prevention market, following Synagis (Sobi) and Beyfortus, potentially increasing competition and eventually impacting pricing, thereby alleviating the burden of RSV on healthcare systems. The drug demonstrated significant efficacy, reducing medically attended lower respiratory infections caused by RSV by over 60% and hospitalizations by over 84%. However, uncertainty looms as the Advisory Committee on Immunization Practices (ACIP), which provides crucial usage recommendations to the CDC, has recently undergone a complete overhaul of its members, introducing unpredictability to its upcoming June meeting where Enflonsia's use was expected to be discussed. Merck plans to start taking orders in July for the 2025 RSV season. This development occurs within a rapidly evolving RSV prevention landscape, which also includes Pfizer's (PFE) maternal vaccine, Abrysvo.

Key Decisions for Investors

• Investors in Merck (MRK) should view this approval as a positive development, potentially expanding its pediatric franchise and revenue, while closely monitoring the market adoption of Enflonsia's single-dose feature and the forthcoming, albeit uncertain, ACIP recommendations.
• Holders of Sanofi (SNY) and AstraZeneca (AZN) should consider the increased competitive pressure from Enflonsia, which, despite identical pricing, may gain market share due to its simplified dosing, although Beyfortus currently maintains an advantage with its broader label for second-season high-risk infants.
• The introduction of a third monoclonal antibody for RSV signals market growth but also heightens competition; investors should monitor for potential pricing shifts and market share realignments among MRK, SNY/AZN, and observe impacts on related products like Pfizer's (PFE) Abrysvo.